Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vonoprazan and Amoxicillin for Helicobacter Pylori Infection (VATH-1)
NCT05590286Phase 4Unknown
- Sponsor
- Hangzhou First People's Hospital
- Start
- Jun 2022
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of vonoprazan in Helicobacter pylori infection (2 arms), sponsored by Hangzhou First People's Hospital. Primary endpoint: Helicobacter Pylori Eradication Rate at 6 weeks. Status: unknown.
02
Drugs
vonoprazan
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on NCT05590286.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05590286.